Publication:
Recent Developments and Future Perspectives of Vaccines and Therapeutic Agents against SARS-CoV2 Using the BCOV_S1_CTD of the S Protein

Simple item page
dc.contributor.authorGupta, Amit
dc.contributor.authorSingh, Ashish P.
dc.contributor.authorSingh, Vinay K.
dc.contributor.authorSinha, Rajeshwar P.
dc.date.accessioned2025-01-28T09:45:09Z
dc.date.available2025-01-28T09:45:09Z
dc.date.issued2023
dc.description.abstractSince the onset of the coronavirus disease 2019 (COVID-19) pandemic, the virus kept developing and mutating into different variants over time, which also gained increased transmissibility and spread in populations at a higher pace, culminating in successive waves of COVID-19 cases. The scientific community has developed vaccines and antiviral agents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease. Realizing that growing SARS-CoV-2 variations significantly impact the efficacy of antiviral therapies and vaccines, we summarize the appearance and attributes of SARS-CoV-2 variants for future perspectives in drug design, providing up-to-date insights for developing therapeutic agents targeting the variants. The Omicron variant is among the most mutated form; its strong transmissibility and immune resistance capacity have prompted international worry. Most mutation sites currently being studied are in the BCOV_S1_CTD of the S protein. Despite this, several hurdles remain, such as developing vaccination and pharmacological treatment efficacies for emerging mutants of SARS-CoV-2 strains. In this review, we present an updated viewpoint on the current issues faced by the emergence of various SARS-CoV-2 variants. Furthermore, we discuss the clinical studies conducted to assist the development and dissemination of vaccines, small molecule therapeutics, and therapeutic antibodies having broad-spectrum action against SARS-CoV-2 strains. � 2023 by the authors.
dc.identifier.doihttps://doi.org/10.3390/v15061234
dc.identifier.issn19994915
dc.identifier.urihttps://dl.bhu.ac.in/ir/handle/123456789/22269
dc.language.isoen
dc.publisherMDPI
dc.subjectantiviral agents
dc.subjectclinical studies
dc.subjectmutant
dc.subjectOmicron variant
dc.subjectSARS-CoV-2
dc.subjectvaccines
dc.titleRecent Developments and Future Perspectives of Vaccines and Therapeutic Agents against SARS-CoV2 Using the BCOV_S1_CTD of the S Protein
dc.typeReview
dspace.entity.typePublication
journal.titleViruses
journalvolume.identifier.volume15

Files

Collections

2023